本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2025 年第二次临时股东大会 2、会议召集人：山西振东制药股份有限公司（以下简称"公司"） 董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、部 门规章、规范性文件及《公司章程》的有关规定。 4、会议召开时间 （1）现场会议时间：2025 年 12 月 18 日 09:00 证券代码：300158 证券简称：振东制药 公告编号：2025-073 山西振东制药股份有限公司 关于召开 2025 年第二次临时股东大会的通知 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的 具体时间为 2025 年 12 月 18 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为2025年12月 18 日 9:15 至 15:00 的任意时间。 5、会议召开方式：现场表决与网络 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-071 山西振东制药股份有限公司 第六届监事会第六次会议决议公告 因公司监事雷振宏先生、李莎莎女士拟参与本次员工持股计划， 须对本议案回避表决。非关联监事人数不足监事会人数的半数，监事 会对本议案无法形成有效决议。本议案将直接提交公司股东大会审议， 并须经出席股东大会的股东所持有效表决权的半数以上通过。 《山西振东制药股份有限公司第四期员工持股计划（草案）>及 其摘要》详见中国证监会创业板指定信息披露网站。 本议案尚需提交公司 2025 年第二次临时股东大会审议。 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山西振东制药股份有限公司（以下简称"公司"）第六届监事会第 六次会议于2025年11月19日9:30通过通讯表决方式召开，会议通知于 2025年11月18日以电话、邮件等方式通知全体监事（经全体监事一致 同意，豁免本次会议通知的时间要求）。本次会议应出席监事3人， 实际出席监事3人，会议由监事会主席雷振宏先生主持。会议符合《公 司法》和《公司章程》的有关规定。 二、 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-070 山西振东制药股份有限公司 第六届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山西振东制药股份有限公司（以下简称"公司"）第六届董事会第 八次会议于 2025 年 11月 19 日上午 9:00 以现场及通讯表决方式召开， 会议通知于 2025 年 11 月 18 日以电话、邮件等方式通知全体董事（经 全体董事一致同意，豁免本次会议通知的时间要求）。会议应出席董 事 9 名，实际出席董事 9 名。会议由公司董事长李昆先生主持，公司 全体监事及高级管理人员列席了会议。本次会议的出席人数、召集、 召开程序和议事内容均符合国家有关法律、法规及《公司章程》的规 定。 二、董事会会议审议情况 1、会议以 9 票同意、0 票反对、0 票弃权，审议通过了《关于为 全资子公司提供担保的议案》。 因经营发展的需要，公司全资子公司山西振东安欣生物制药有限 公司（以下简称"安欣制药"）、山西振东泰盛制药有限公司（以下简 称"泰盛制药"）拟向金融机构申请不超过人 ...

格隆汇11月19日丨振东制药(300158.SZ)公布第四期员工持股计划，员工持股计划筹集资金总额上限为 2.5亿元，以"份"作为认购单位，每份份额为1元，本员工持股计划的份数上限为2.5亿份。员工持股计划 持有的股票总数不包括员工在公司首次公开发行股票上市前获得的股份、通过二级市场自行购买的股份 及通过股权激励获得的股份。本期员工持股计划的参与对象为公司员工，总人数不超过2000人，具体参 加人数根据员工实际缴款情况确定。 ...

格隆汇11月19日丨振东制药(300158.SZ)公布，公司第三期员工持股计划（简称"本次员工持股计划"）所 持公司股票已通过集中竞价交易方式全部出售完毕。截至本公告披露日，本次员工持股计划所持公司股 票已出售完毕暨实施完成。本次员工持股计划于2025年9月9日至2025年11月19日期间，通过集中竞价方 式累计出售公司股票38,967,619股，占公司当前总股本的3.8761%。 ...

融券方面，振东制药11月17日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量1.77万股，融券余额12.73万元，超过近一年80%分位水平，处于高位。 11月17日，振东制药跌2.44%，成交额3.41亿元。两融数据显示，当日振东制药获融资买入额2023.66万 元，融资偿还3241.45万元，融资净买入-1217.79万元。截至11月17日，振东制药融资融券余额合计3.72 亿元。 融资方面，振东制药当日融资买入2023.66万元。当前融资余额3.72亿元，占流通市值的5.14%，融资余 额超过近一年80%分位水平，处于高位。 机构持仓方面，截止2025年9月30日，振东制药十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股3746.00万股，相比上期增加2948.96万股。 资料显示，山西振东制药股份有限公司位于山西省长治市上党区光明南路振东科技园，成立日期1995年 11月15日，上市日期2011年1月7日，公司主营业务涉及肿瘤、毛发、消化、泌尿、心脑等仿制药、创新 药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链 ...

Core Viewpoint - The company, Zhendong Pharmaceutical, is focusing on enhancing its operational performance and product competitiveness to improve long-term shareholder value, despite facing challenges in stock price compared to peers [2]. Group 1: Stock Performance - As of November 14, 2025, Zhendong Pharmaceutical's stock closed at 7.37 yuan, reflecting a 3.08% increase with a turnover rate of 7.92% and a trading volume of 795,400 shares, amounting to a transaction value of 587 million yuan [1]. - On the same day, there was a net outflow of 17.61 million yuan from major funds, indicating continued withdrawal of institutional investment [2]. Group 2: Company Strategy - The company is committed to optimizing its product matrix, strengthening the competitiveness of its product pipeline, and enhancing channel development to boost performance [2]. - The company has completed its share repurchase plan, which is part of its strategy to return value to shareholders [2].

Core Viewpoint - Shanxi Province's Changzhi City is pursuing high-quality development through a model that integrates characteristic agriculture, green industry, and cultural tourism, supported by targeted financial services from Postal Savings Bank [1] Group 1: Agricultural Financial Support - Changzhi City has notable characteristic agricultural products such as Shangdang party ginseng, Qinzhou yellow millet, and Changzi green peppers, with Postal Savings Bank focusing on the city's five major characteristic industry clusters to provide comprehensive financial services [2] - Shanxi Qinzhou Yellow Millet (Group) Co., Ltd. has received 8 million yuan in credit support from Postal Savings Bank to upgrade its processing capabilities and expand its product range, leading to an annual processing capacity exceeding 30,000 tons and benefiting over 20,000 farming households [2][3] - As of October 2023, Postal Savings Bank's agricultural loan balance reached 13.8 billion yuan, with over 6.5 billion yuan specifically for characteristic agriculture, serving 78 leading agricultural enterprises and over 1,200 cooperatives [3] Group 2: Traditional Industry Transformation - Postal Savings Bank is actively supporting the transformation of traditional industries in Changzhi City, focusing on green and low-carbon initiatives, and has developed innovative financial products to facilitate this transition [4] - Jin Ding Steel Group has received 100 million yuan in transformation loans, which are linked to energy consumption intensity, promoting carbon reduction and enabling the completion of three intelligent production line upgrades [4] - The bank has established a "special credit + green channel" service mechanism to support sectors like traditional Chinese medicine and new energy, enhancing the value of local medicinal materials [5] Group 3: Enhanced Service Efficiency - Postal Savings Bank has implemented a "one customer, one strategy, one enterprise" approach to improve service efficiency and reduce approval times for financial products tailored to diverse business needs [6] - New financial products such as "industrial flow loans" and "technical reform special loans" have been introduced to meet the funding requirements of various industries, including aluminum processing and logistics [6] - The bank is also offering interest rate discounts and fee reductions to lower financing costs for enterprises [6]

Core Viewpoint - On November 14, the A-share market experienced a collective decline across the three major indices, with the Shanghai Composite Index down by 0.97%, the Shenzhen Component Index down by 1.93%, and the ChiNext Index down by 2.82% [1] Market Performance - The total trading volume in the Shanghai and Shenzhen markets was approximately 1,958.08 billion yuan, a decrease of about 83.88 billion yuan compared to the previous trading day [1] - Out of the total stocks, 1,961 stocks rose while 3,323 stocks fell, with 89 stocks hitting the daily limit up and 9 stocks hitting the daily limit down [1] Sector Performance - The Hainan and Fujian sectors showed strength, with pharmaceutical stocks related to influenza leading in gains, while the gas and photovoltaic equipment sectors also performed well [1] - The storage chip sector underwent a correction, along with adjustments in the CPO and food and beverage sectors [1] Regional Performance - Despite the overall decline in the three major indices, the Shanxi sector demonstrated resilience, with a slight increase of 0.21% on November 14 [1] Individual Stock Performance - In the Shanxi sector, three stocks hit the daily limit up, with China New Energy and Antai Group reaching limit up around 10 AM, ultimately closing with gains of 10.11% and 10.02% respectively; Yongtai Energy also hit limit up in the afternoon, closing with a gain of 9.82% [1] - Additionally, two other stocks in the Shanxi sector rose by over 2%, with Zhendong Pharmaceutical up by 3.08% and Jinlihua Electric up by 2.80% [1] - Leading the decline was Lu Hua Technology, which fell by 4.16% compared to the previous trading day; other notable decliners included Keda Control, Jinkong Coal Industry, Huayang Co., and Northern Copper, with declines of 3.73%, 3.46%, 3.46%, and 3.31% respectively [1]

Group 1 - Longjian Co., Ltd. won a bid for a highway maintenance project in Heilongjiang with a contract value of 483 million yuan, accounting for 2.64% of the company's expected revenue for 2024 [1] - Transsion Holdings plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] - Good Home's controlling shareholder intends to reduce its stake by up to 2.7%, equivalent to no more than 39.4468 million shares [1][2] Group 2 - Xinhua Insurance reported a cumulative premium income of 181.973 billion yuan from January to October, representing a year-on-year growth of 17% [2][4] - Zhejiang Jiaokao is part of a consortium that plans to bid for a new urbanization project with an estimated total investment of 11.103 billion yuan [4] Group 3 - Changchun High-tech received approval for clinical trials of a vaccine for adolescents and adults [6] - XinNuoWei's application for the listing of Pertuzumab injection has been accepted, targeting HER2-positive breast cancer [8] - Dash Smart won a bid for an intelligent project at the new Huanggang Port inspection building, valued at 55.056 million yuan, which is 1.74% of its expected revenue for 2024 [8] Group 4 - Electronic City is involved in a lawsuit for debt recovery, with the amount in dispute estimated at 777 million yuan [9] - Haibo Technology signed a strategic cooperation agreement with CATL for a cumulative procurement of no less than 200 GWh of electricity from 2026 to 2028 [10] Group 5 - Renfu Pharmaceutical's HW231019 tablets have entered the second phase of clinical trials for postoperative pain relief [11] - Tonghua Dongbao received a drug registration certificate for Aspart Insulin injection from the Dominican Republic [11] Group 6 - Shaanxi Construction reported winning major projects worth a total of 1.016 billion yuan in October [12] - Fuzhou Environmental Protection plans to change its stock name to "Fuzhou Technology" [12] Group 7 - Panlong Pharmaceutical's gel patch for knee osteoarthritis has received approval for clinical trials [15] - Zhongyida's application for a specific stock issuance has been terminated by the Shanghai Stock Exchange [16] Group 8 - Zhizhong Home's controlling shareholder reduced its holdings of convertible bonds by 905,000 units, accounting for 13.51% of the total issued [19] - Haibo Co., Ltd. plans to establish a subsidiary with an investment of 1 billion yuan for high-end component projects [21] Group 9 - Caina Co. plans to use 57 million yuan of idle funds to purchase structured deposits [23] - Zhendong Pharmaceutical's new drug for acute ischemic stroke has entered the IIa phase of clinical trials [25] Group 10 - Weiman Sealing's overseas subsidiary plans to lease a factory in Saudi Arabia for 5 years at a total rent of approximately 54.039 million yuan [26] - Yiling Pharmaceutical's application for Memantine Hydrochloride has been approved for market entry [28] Group 11 - Dongfang Zhizao plans to acquire 70% of Saifu Machinery for 27.4887 million yuan [30] - JianKai Technology's actual controller intends to transfer 3% of the company's shares through inquiry [31] Group 12 - Rejing Bio plans to repurchase shares worth between 100 million and 200 million yuan [32] - Bangji Technology has decided to terminate a major asset restructuring project due to failure to reach an agreement [34] Group 13 - Huadong Pharmaceutical's application for the marketing license of a new drug has been accepted [36] - Zhonggu Logistics' shareholder plans to reduce its stake by up to 3% [38] Group 14 - Bohui Innovation's subsidiary received approval for a clinical trial of a vaccine for invasive infections [40] - Shannon Chip's shareholder pledged 0.27% of the company's shares for financing [42] Group 15 - Shanghai Petrochemical appointed a new general manager [44] - Jiaojian Co. plans to reduce the holdings of some directors and executives by up to 0.35% [46] Group 16 - Weiting Electric plans to raise no more than 300 million yuan through a private placement [47] - Zhongjin Irradiation plans to invest approximately 200 million yuan in an electronic accelerator manufacturing project [49] Group 17 - Tongxing Technology signed a framework agreement to invest 3.2 billion yuan in a sodium battery project [50] - Hongri Da plans to establish a subsidiary focused on semiconductor packaging [51] Group 18 - Shanghai Kaibao's new drug for acute ischemic stroke has received approval for clinical trials [53] - Yitong Century announced a change in its control structure, becoming a company without a controlling shareholder [55]